dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Other DMPK family kinases (type: enzyme)
Target: citron rho-interacting serine/threonine kinase

Ligand: C3TD879 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pKd
Reference (Journal): Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase.
Published in: J Med Chem

Ligand: C3TD879 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pIC50
Reference (Journal): Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase.
Published in: J Med Chem
Target family: Other immune checkpoint proteins (type: other_protein)
Target: TIM3 (CD366)

Ligand: sabatolimab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.319999694824219 pIC50
Reference (Journal): Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Published in: Immunother Adv
Target family: Other immune checkpoint proteins (type: other_protein)
Target: B7-H3 (CD276)

Ligand: enoblituzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.610000133514404 pKd
Reference (Journal): Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Published in: Clin Cancer Res

Ligand: enoblituzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.650000095367432 pKd
Reference (Journal): Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Published in: Clin Cancer Res

Ligand: obrindatamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Antibodies reactive with B7-H3 and uses thereof
Target family: Other immune checkpoint proteins (type: other_protein)
Target: CD22

Ligand: inotuzumab ozogamicin (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA & FDA (2017)
Primary target: yes
Median affinity: 9.699999809265137 pKd
Reference (Journal): Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
Published in: Blood

Ligand: moxetumomab pasudotox (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2021)
Primary target: yes
Median affinity: 8.220000267028809 pKd
Reference (Journal): Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Published in: Clin Cancer Res

Ligand: moxetumomab pasudotox (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2021)
Primary target: yes
Median affinity: 8.220000267028809 pKd
Reference (Journal): Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Published in: J Clin Oncol

Ligand: moxetumomab pasudotox (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2021)
Primary target: yes
Median affinity: 8.220000267028809 pKd
Reference (Patent): Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells.
Target family: Other immune checkpoint proteins (type: other_protein)
Target: CD28

Ligand: lulizumab pegol (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  pKd
Reference (Journal): A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.
Published in: J Immunol
Target family: Other immune checkpoint proteins (type: other_protein)
Target: CD33

Ligand: gemtuzumab ozogamicin (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2000), EMA (2018)
Primary target: yes
Median affinity:  -
Reference (Journal): Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
Published in: Leukemia

Ligand: lintuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 10 pKd
Reference (Journal): Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Published in: Cancer Res

Ligand: vadastuximab talirine (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.300000190734863 pKd
Reference (Journal): SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
Published in: Blood
Target family: Other immune checkpoint proteins (type: other_protein)
Target: CD80

Ligand: abatacept (Peptide)
Interaction type: Fusion protein
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2005), EMA (2005)
Primary target: yes
Median affinity: 7.920000076293945 pKd
Reference (Journal): CTLA-4 is a second receptor for the B cell activation antigen B7.
Published in: J Exp Med

Ligand: abatacept (Peptide)
Interaction type: Fusion protein
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2005), EMA (2005)
Primary target: yes
Median affinity: 7.920000076293945 pKd
Reference (Journal): Update on the use of abatacept for the treatment of rheumatoid arthritis.
Published in: Expert Rev Clin Immunol

Ligand: belatacept (Peptide)
Interaction type: Fusion protein
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2011), EMA (2011)
Primary target: yes
Median affinity:  -
Reference (Journal): Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.
Published in: Transplantation
Target family: Other immune checkpoint proteins (type: other_protein)
Target: CD86

Ligand: abatacept (Peptide)
Interaction type: Fusion protein
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2005), EMA (2005)
Primary target: yes
Median affinity: 7.920000076293945 pKd
Reference (Journal): Update on the use of abatacept for the treatment of rheumatoid arthritis.
Published in: Expert Rev Clin Immunol

Ligand: abatacept (Peptide)
Interaction type: Fusion protein
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2005), EMA (2005)
Primary target: yes
Median affinity: 7.920000076293945 pKd
Reference (Journal): CTLA-4 is a second receptor for the B cell activation antigen B7.
Published in: J Exp Med

Ligand: belatacept (Peptide)
Interaction type: Fusion protein
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2011), EMA (2011)
Primary target: yes
Median affinity:  -
Reference (Journal): Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.
Published in: Transplantation
Target family: Other immune checkpoint proteins (type: other_protein)
Target: cytotoxic T-lymphocyte-associated protein 4 (CD152)

Ligand: cadonilimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: China NMPA (2022)
Primary target: yes
Median affinity: 10.100000381469727 pEC50
Reference (Journal): Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.
Published in: MAbs

Ligand: ipilimumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA and EMA (2011)
Primary target: yes
Median affinity: 9 pKd
Reference (Patent): Human ctla-4 antibodies and their uses.

Ligand: nurulimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Human CTLA-4 antibodies

Ligand: tremelimumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2022), EMA (2023)
Primary target: yes
Median affinity: 8.90999984741211 pKd
Reference (Patent): Human monoclonal antibodies to CTLA-4.
Target family: Other immune checkpoint proteins (type: other_protein)
Target: ICOS (CD278)

Ligand: feladilimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.020000457763672 pKd
Reference (Patent): Agonistic icos binding proteins

Ligand: feladilimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.869999885559082 pKd
Reference (Patent): Agonistic icos binding proteins
Target family: Other immune checkpoint proteins (type: other_protein)
Target: LAG3 (CD223)

Ligand: relatlimab (Antibody)
Interaction type: Antibody
Action: Antagonist
Ligand approved: yes
Approval source: EMA & FDA (2022)
Primary target: yes
Median affinity:  -
Reference (Patent): Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
Target family: Other immune checkpoint proteins (type: other_protein)
Target: TIM3 (CD366)

Ligand: sabatolimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.140000343322754 pKd
Reference (Journal): Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Published in: Immunother Adv

Ligand: sabatolimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.779999732971191 pKd
Reference (Journal): Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Published in: Immunother Adv
Target family: Other PEK family kinases (type: enzyme)
Target: eukaryotic translation initiation factor 2 alpha kinase 1

Ligand: RIPK1 inhibitor 22b (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pIC50
Reference (Journal): Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Published in: J Med Chem

Ligand: compound 27 [PMID: 19854648] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.199999809265137 pIC50
Reference (Journal): Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase.
Published in: Bioorg Med Chem Lett
Target family: Other PEK family kinases (type: enzyme)
Target: eukaryotic translation initiation factor 2 alpha kinase 2

Ligand: PKR inhibitor (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.679999828338623 pIC50
Reference (Journal): Small molecule inhibitors of the RNA-dependent protein kinase.
Published in: Biochem Biophys Res Commun

Ligand: indirubin derivative E804 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7 pIC50
Reference (Journal): Identification of new inhibitors of protein kinase R guided by statistical modeling.
Published in: Bioorg Med Chem Lett

Ligand: Cdk2 inhibitor IV (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pIC50
Reference (Journal): Identification of new inhibitors of protein kinase R guided by statistical modeling.
Published in: Bioorg Med Chem Lett
Target family: Other PIKK family kinases (type: enzyme)
Target: ATM serine/threonine kinase

Ligand: KU-60019 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.199999809265137 pIC50
Reference (Journal): Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.
Published in: Mol Cancer Ther

Ligand: KU-55933 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.889999866485596 pIC50
Reference (Journal): Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
Published in: Cancer Res

Ligand: CP466722 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation
Published in: Cancer Res

Ligand: berzosertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.46999979019165 pKi
Reference (Journal): Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
Published in: Cell Death Dis

Ligand: BAY-8400 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.710000038146973 pIC50
Reference (Journal): BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
Published in: J Med Chem

Ligand: AZD1390 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.109999656677246 pIC50
Reference (Journal): The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Published in: Sci Adv

Ligand: AZD0156 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.239999771118164 pIC50
Reference (Journal): The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
Published in: J Med Chem

Ligand: A011 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): Discovery of [1,2,3]Triazolo[4,5-c]quinoline Derivatives as a New Class of Ataxia-Telangiectasia Mutated Kinase Inhibitors
Published in: ACS Med Chem Lett
Target family: Other PIKK family kinases (type: enzyme)
Target: ATM serine/threonine kinase

Ligand: lartesertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.699999809265137 pIC50
Reference (Patent): Imidazolonylquinoline compounds and therapeutic uses thereof

Ligand: KU-55933 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.65999984741211 pKi
Reference (Journal): Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
Published in: Cancer Res
Target family: Other-unique family (type: enzyme)
Target: serine/threonine kinase 31

Ligand: compound 25 [PMID: 17935989] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pKi
Reference (Journal): Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.
Published in: Bioorg Med Chem Lett
Target family: Other viral proteins (type: other_protein)
Target: Zika virus genome polyprotein

Ligand: NSC157058 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.090000152587891 pIC50
Reference (Journal): Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists.
Published in: Antiviral Res
Target family: Other viral proteins (type: other_protein)
Target: Hepatitis C virus genome polyprotein

Ligand: simeprevir (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2013), EMA (2014)
Primary target: yes
Median affinity: 9.4399995803833 pKi
Reference (Journal): Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.
Published in: Bioorg Med Chem Lett
Target family: Oxoglutarate receptor (type: gpcr)
Target: oxoglutarate receptor

Ligand: [3H]LTE4 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.6 pKd
Reference (Journal): Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand.
Published in: J Biol Chem

Ligand: α-ketoglutaric acid (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein-Coupled Receptors.
Published in: J Biomol Screen

Ligand: α-ketoglutaric acid (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors.
Published in: Nature
Target family: P2A P-type ATPases: Ca<sup>2+</sup>-ATPases (type: transporter)
Target: SERCA1

Ligand: CDN1163 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 5.21999979019165 pEC50
Reference (Journal): Stimulation of Ca<sup>2+</sup> -ATPase Transport Activity by a Small-Molecule Drug.
Published in: ChemMedChem

Ligand: TGN4 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 8.920000076293945 pIC50
Reference (Journal): Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.
Published in: J Med Chem
Target family: P2X receptors (type: lgic)
Target: P2X5

Ligand: ATP (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6 pEC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem
Target family: P2X receptors (type: lgic)
Target: P2X3

Ligand: TNP-ATP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Median affinity: 8.9 pIC50
Reference (Journal): Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors.
Published in: Mol Pharmacol

Ligand: suramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 4.829999923706055 pIC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem

Ligand: sivopixant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.380000114440918 pIC50
Reference (Journal): Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists.
Published in: Bioorg Med Chem Lett

Ligand: suramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 5.519999980926514 pIC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem
Target family: P2X receptors (type: lgic)
Target: P2X5

Ligand: suramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 5.400000095367432 pIC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem
Target family: P2X receptors (type: lgic)
Target: P2X6

Ligand: ATP (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6 pEC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem
Target family: P2X receptors (type: lgic)
Target: P2X2

Ligand: ATP (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pEC50
Reference (Journal): Development of selective agonists and antagonists of P2Y receptors.
Published in: Purinergic Signal

Ligand: NF770 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): P2X receptors as drug targets.
Published in: Mol Pharmacol

Ligand: NF778 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): P2X receptors as drug targets.
Published in: Mol Pharmacol

Ligand: PSB-10211 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): P2X receptors as drug targets.
Published in: Mol Pharmacol

Ligand: suramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 4.980000019073486 pIC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem
Target family: P2Y receptors (type: gpcr)
Target: P2Y<sub>1</sub> receptor

Ligand: [3H]2MeSADP (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pKd
Reference (Journal): Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor.
Published in: Mol Pharmacol
Target family: P2Y receptors (type: gpcr)
Target: P2Y<sub>1</sub> receptor

Ligand: [32P]MRS2500 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.4 pKd
Reference (Journal): [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors.
Published in: Br J Pharmacol